PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced results of a pre-specified secondary analysis of the Eliquis Phase 3 AMPLIFY-EXT trial (Apixaban after the initial Management of PuLmonary embolIsm and deep vein thrombosis with First-line therapY-EXTended Treatment). The analys […]
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB:SNTI) today announced the closing of enrollment in its ongoing Phase 1b/2a open-label, multiple-dose, dose-escalation clinical trial of SNS01-T, a first-in-class modulator of eukaryotic translation initiation factor 5A (eIF5A), in patients with relapsed or refr […]
OVERLAND PARK, Kan.--(BUSINESS WIRE)--Netsmart today announced that its myAvatar™ ONC 2014 solution has been certified as an Inpatient Complete EHR, 2014 Edition (Meaningful Use Stage 2). Using the myAvatar CareRecord™, hospitals, including those that serve the behavioral health community, can qualify for Meaningful Use Stage 2 incentive funding and improve […]
MONTCLAIR, N.J.--(BUSINESS WIRE)--MetaStat's CEO, Oscar L. Bronsther, M.D., Chief Executive Officer, is scheduled to present at the Rodman Conference on September 10, 2014 at 2:05 pm EDT. His presentation will be webcast.
PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today announced that a series of abstracts highlighting data from its Infectious Disease portfolio will be presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), which takes place in Washington, DC from September 5-9, 2014. Data will be presented o […]
BASKING RIDGE, N.J.--(BUSINESS WIRE)--Ipsen N.A. (Euronext: IPN; ADR: IPSEY) today announced that a new supply of Increlex® will be available starting in September 2014. In collaboration with the U.S. Food and Drug Administration (FDA), Ipsen is releasing a second batch of Increlex® in 2014. The first batch was made available for distribution in June of 2014 […]
NEW YORK & WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Merck & Co. Inc. (NYSE:MRK), known as MSD outside the United States and Canada, through a subsidiary, announced today that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s crizotinib (XALKORI®) with Merck’s investiga […]